arrow
P

Piero Barbanti

San Raffaele University
H指数:44
被引数:6,051

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Migraine in Real-World Clinical Practice: Patient Burden, Healthcare Utilization and Unmet Needs—A Cross-Sectional Analysis of the I-GRAINE Study

偏头痛在真实世界临床实践中的患者负担、医疗资源利用及未满足需求——I-GRAINE研究的横断面分析

2026-09-290
OA
Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study

更正:艾普尼珠单抗治疗偏头痛48周的真实世界响应和超响应:前瞻性多中心EMBRACE III研究

2026-07-230
OAAI
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study

偏头痛中艾替利珠单抗48周的实际世界反应和超反应:前瞻性多中心EMBRACE III研究

2026-06-090
OAAI
Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in Italy

在偏头痛管理中构建桥梁:意大利初级保健和专科护理最佳实践的共识路径

2026-05-190
OAAI
Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans

中度至重度急性偏头痛发作:关于三叉神经痛药物和三叉神经痛药物-非甾体抗炎药组合在个体化治疗计划中应用的论文

2025-12-180
OAAI
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)

绘制真实世界偏头痛患者画像:来自意大利国家偏头痛登记系统(I-GRAINE)的社会人口学、生活方式和临床数据的公共卫生见解

2025-10-030
OA
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

GIANT:一项关于在多次治疗失败的偏头痛患者中阿托 gepant 的有效性、安全性和耐受性的前瞻性、多中心、真实世界研究

2025-05-190
OA
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study (Vol 13, Pg 611, 2024)
2024-08-060
OAAI
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
2024-05-2210
PRE
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
2024-03-074
OAAI
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
2024-01-170
OAAI
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
2023-03-2320
OAAI